Search This Blog

Wednesday, July 29, 2020

FDA OKs pooled sample testing for COVID-19 at Quest

The FDA has signed off on pooled sample testing at Quest Diagnostics (NYSE:DGX) for the detection of SARS-CoV-2. The new method will allow the reference lab to boost daily testing capacity to ~170K from 135K in the next few weeks with an upside of 185K tests by Labor Day.
Related ticker: LabCorp (NYSE:LH)

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)